Citius Oncology, Inc.

Citius Oncology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative targeted oncology therapies. The company's mission is to bring novel treatments to patients with unmet medical needs in the oncology space. Its headquarters are located in Cranford, New Jersey.

Citius Oncology's primary product is LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein. This therapy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The company launched LYMPHIR commercially in the U.S. in December 2025 and has since begun expanding its international distribution to Europe.

Having transitioned to a commercial-stage oncology company, Citius Oncology reported its first revenue of $3.9 million from LYMPHIR sales in December 2025. The company estimates the initial market for LYMPHIR to exceed $400 million, noting it is currently underserved by existing therapies. Leonard L. Mazur serves as the Chief Executive Officer of Citius Oncology, Inc., and also holds the position of Chairman and CEO of its parent company, Citius Pharmaceuticals, Inc.